Source:http://linkedlifedata.com/resource/pubmed/id/17453364
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2007-4-24
|
pubmed:abstractText |
Chemotherapy dosing only based on body surface area (BSA) results in marked pharmacokinetic and toxicity variations, which may result in an inferior outcome for some patients. A toxicity-based dosing schedule for individually tailored treatment with granulocyte colony-stimulating factor (G-CSF) supported 5-fluorouracil (F), epirubicin (E) and cyclophosphamide (C) (dFEC) was developed and studied in patients with metastatic breast cancer with the purpose to determine its efficiency and toxicity. Twenty-six women, median age 48 years, were included and the individual E and C doses were tailored stepwise based on the recorded hematological toxicity. Twenty-one patients (81%; 95% confidence interval (CI), 66% to 96%) had an objective response, including six complete responses (23%; CI, 7%-39%). At median follow-up of 113 months, the median time to progression and median overall survival were 14 and 36 months, respectively. The delivered dose intensity was high but varied substantially between patients (ranges F 126-202, E 14.4-36.0, C 160-510 mg/m(2)/w). The dominating grade III/IV toxicity was nausea (12% of patients) and febrile neutropenia (31% of patients). The tailored and dose-escalated FEC was highly active and feasible in metastatic breast cancer and may provide a pragmatic way of overcoming the shortcomings of standard BSA-based dosing.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0284-186X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
46
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
165-71
|
pubmed:dateRevised |
2009-5-12
|
pubmed:meshHeading |
pubmed-meshheading:17453364-Adult,
pubmed-meshheading:17453364-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17453364-Breast Neoplasms,
pubmed-meshheading:17453364-Cyclophosphamide,
pubmed-meshheading:17453364-Epirubicin,
pubmed-meshheading:17453364-Female,
pubmed-meshheading:17453364-Fluorouracil,
pubmed-meshheading:17453364-Humans,
pubmed-meshheading:17453364-Middle Aged,
pubmed-meshheading:17453364-Quality of Life,
pubmed-meshheading:17453364-Survival,
pubmed-meshheading:17453364-Treatment Outcome
|
pubmed:year |
2007
|
pubmed:articleTitle |
Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer.
|
pubmed:affiliation |
Department of Oncology, Uppsala University Hospital, Uppsala, Sweden. henrik.lindman@onkologi.uu.se
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|